Compare · MYO vs SNN
MYO vs SNN
Side-by-side comparison of Myomo Inc. (MYO) and Smith & Nephew SNATS Inc. (SNN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MYO and SNN operate in Industrial Specialties (Health Care), so they compete in similar markets.
- SNN is the larger of the two at $12.41B, about 211.8x MYO ($58.6M).
- SNN has been more active in the news (14 items in the past 4 weeks vs 10 for MYO).
- SNN has more recent analyst coverage (25 ratings vs 3 for MYO).
- Company
- Myomo Inc.
- Smith & Nephew SNATS Inc.
- Price
- -
- -
- Market cap
- $58.6M
- $12.41B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- AMEX
- NYSE
- IPO
- 2017
- News (4w)
- 10
- 14
- Recent ratings
- 3
- 25
Myomo Inc.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to restore function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Smith & Nephew SNATS Inc.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
Latest MYO
- Amendment: Chief Medical Officer Kovelman Harry sold $30,329 worth of shares (17,500 units at $1.73), decreasing direct ownership by 14% to 105,733 units (SEC Form 4)
- Chief Medical Officer Kovelman Harry sold $29,896 worth of shares (17,250 units at $1.73), decreasing direct ownership by 14% to 105,983 units (SEC Form 4)
- Chief Medical Officer Kovelman Harry covered exercise/tax liability with 22,457 shares and was granted 55,149 shares, increasing direct ownership by 36% to 123,233 units (SEC Form 4)
- Chief Commercial Officer Mitchell Micah was granted 58,409 shares and covered exercise/tax liability with 21,559 shares, increasing direct ownership by 39% to 130,738 units (SEC Form 4)
- Chief Executive Officer Gudonis Paul R was granted 146,909 shares, increasing direct ownership by 11% to 1,434,679 units (SEC Form 4)
- Chief Financial Officer Henry David A was granted 68,644 shares and covered exercise/tax liability with 25,310 shares, increasing direct ownership by 10% to 470,163 units (SEC Form 4)
- SEC Form S-8 filed by Myomo Inc.
- SEC Form 10-Q filed by Myomo Inc.
- Myomo Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Myomo Reports Second Quarter 2026 Financial and Operating Results
Latest SNN
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- Smith+Nephew and Imperial College London launch centre to accelerate innovation in surgical robotics
- Smith+Nephew’s new FLOW FLEXTEND™ COBLATION™ Wand improves access¹* and resection efficiency²** for complex hip procedures vs. fixed-angle options
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- Smith & Nephew downgraded by Analyst
- Smith+Nephew celebrates mobility, recovery and football's greatest traditions during Pro Football Hall of Fame Enshrinement Week